-
REAL-WORLD EFFECTIVENESS OF STATIN THERAPY AND PREDICTIVE MODELING OF ADHERENCE AMONG PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA
Mar 18, 2026, 21:38 PM -
ASSESSING THE IMPACT OF INCLUSION OF PATIENTS WITH MISSING EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS IN REAL-WORLD OUTCOMES OF THIRD-LINE OR LATER (3L+) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF AI ROBOTIC-ASSISTED RADICAL PROSTATECTOMY
Mar 18, 2026, 21:38 PM -
DEVELOPING A NOVEL PRO MEASURE IN MULTIPLE GLOBAL REGIONS AND LANGUAGES FOR KEY CONTRACEPTIVE SIDE EFFECTS
Mar 18, 2026, 21:38 PM -
WHEN THE TAIL WAGS THE DOG: RETHINKING PARTITIONED SURVIVAL MODELLING IN ONCOLOGY
Mar 18, 2026, 21:38 PM -
ASSOCIATION OF SOCIAL DETERMINANTS OF HEALTH WITH RARE CANCER BURDEN IN THE UNITED STATES: A MEPS-BASED ANALYSIS
Mar 18, 2026, 21:38 PM -
DISPROPORTIONALITY ANALYSIS AND MULTIMODAL GENETIC ASSESSMENT OF PAPILLEDEMA ASSOCIATED WITH PROTEASOME INHIBITORS
Mar 18, 2026, 21:38 PM -
SOCIO-DEMOGRAPHIC DISPARITIES IN HUMAN PAPILLOMAVIRUS VACCINATION AMONG U.S. ADULTS, BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM 2017-2022
Mar 18, 2026, 21:38 PM -
PREPARING FOR THE NEXT ACCESS PARADIGM: TRANSITIONING FROM A REBATE-DOMINANT MARKET TO EU-STYLE EVIDENCE-BASED VALUE TO MAXIMIZE US PAYER COVERAGE
Mar 18, 2026, 21:38 PM -
COST-SAVINGS ASSOCIATED WITH VENETOCLAX-OBINUTUZUMAB VERSUS COVALENT BRUTON’S TYROSINE KINASE INHIBITOR IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD STUDY
Mar 18, 2026, 21:38 PM -
UPTAKE OF THE RSVPREF VACCINE DURING PREGNANCY: ASSOCIATIONS WITH SOCIOECONOMIC STATUS, PRENATAL CARE UTILIZATION, AND MATERNAL RISK FACTORS
Mar 18, 2026, 21:38 PM -
THE POTENTIAL EARLY IMPACT OF THE INFLATION REDUCTION ACT ON BUY-SIDE VALUATION METHODOLOGIES AND TRANSACTION STRUCTURING IN THE PHARMACEUTICAL INDUSTRY
Mar 18, 2026, 21:38 PM -
ESTIMATION OF HEALTH-STATE UTILITY VALUES IN PHENYLKETONURIA (PKU), VIA CLINICAL-EXPERT PROXY ASSESSMENT WITH A GENERIC MEASURE (SF-12V2) OF PATIENT-REPORTED IMPACTS FROM A DISEASE-SPECIFIC MEASURE (PKU-QOL): INTERIM RESULTS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SEMAGLUTIDE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS UNDER MEDICARE DRUG PRICE NEGOTIATIONS
Mar 18, 2026, 21:38 PM -
UNDERSTANDING PRIORITIES IN HEALTH ECONOMICS: MAPPING COST-EFFECTIVENESS AND DISEASE BURDEN TRENDS
Mar 18, 2026, 21:38 PM -
UNDERSTANDING STAKEHOLDER PERSPECTIVES BETWEEN ENDOVASCULAR AND HYBRID REPAIR FOR THORACIC AORTIC ANEURYSMS AND DISSECTIONS INVOLVING THE LEFT SUBCLAVIAN ARTERY
Mar 18, 2026, 21:38 PM -
ASSESSING THE BURDEN OF HIDRADENITIS SUPPURATIVA AND THE INFLUENCE OF SOCIAL DETERMINANTS OF HEALTH ON PATIENT-REPORTED QUALITYOF LIFE
Mar 18, 2026, 21:38 PM -
USING SOCIAL DETERMINANTS OF HEALTH ICD-10 Z-CODES TO IDENTIFY NON-MEDICAL FACTORS AMONG ASTHMA HOSPITALIZATIONS IN THE UNITED STATES, 2016-2022
Mar 18, 2026, 21:38 PM -
IDENTIFYING MEANINGFUL PATIENT SAVINGS ON GENERICS: DIRECT-TO-CONSUMER PRICES VS COMMERCIAL INSURANCE
Mar 18, 2026, 21:38 PM -
PSYCHOMETRIC VALIDATION OF THE QLQ-AA/PNH-54 BASED ON A POOLED DATASET OF A CLINICAL TRIAL AND TWO REAL-WORLD STUDIES OF CROVALIMAB IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Mar 18, 2026, 21:38 PM
